Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
37
SABS Quote, Financials, Valuation and Earnings
Last price:
$3.89
Seasonality move
:
-19.14%
Day range:
$3.83 - $3.97
52-week range:
$1.00 - $6.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
884.93x
P/B ratio:
1.81x
Volume:
205.3K
Avg. volume:
764.8K
1-year change:
210.4%
Market cap:
$274.1M
Revenue:
--
EPS (TTM):
-$2.67
Analysts' Opinion
-
Consensus RatingSAB Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.50, SAB Biotherapeutics, Inc. has an estimated upside of 144.85% from its current price of $3.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing -- downside risk from its current price of $3.88.
Fair Value
-
According to the consensus of 8 analysts, SAB Biotherapeutics, Inc. has 144.85% upside to fair value with a price target of $9.50 per share.
SABS vs. S&P 500
-
Over the past 5 trading days, SAB Biotherapeutics, Inc. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
SAB Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
SAB Biotherapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter SAB Biotherapeutics, Inc. reported revenues of --.
Earnings Growth
-
SAB Biotherapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter SAB Biotherapeutics, Inc. reported earnings per share of -$0.81.
Enterprise value:
182M
EV / Invested capital:
--
Price / LTM sales:
884.93x
EV / EBIT:
--
EV / Revenue:
681.06x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.98x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.1M
Return On Assets:
-13.57%
Net Income Margin (TTM):
-18629.56%
Return On Equity:
-17.05%
Return On Invested Capital:
-15.79%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $2.2M | $1.3M | -- | $114.7K | -- | |
| Gross Profit | -$1.5M | -$3.4M | -$3.1M | -$671K | -$763.3K | |
| Operating Income | -$38.1M | -$42.9M | -$49M | -$10M | -$15.8M | |
| EBITDA | -$34.3M | -$38.2M | -$45.8M | -$9.2M | -$15M | |
| Diluted EPS | -$7.65 | -$3.68 | -$2.67 | -$1.23 | -$0.81 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $50.2M | $22.1M | $58.9M | $23.8M | $101.1M | |
| Total Assets | $81.1M | $50.9M | $83.9M | $46.1M | $174.5M | |
| Current Liabilities | $26.5M | $15M | $10.8M | $8M | $10.7M | |
| Total Liabilities | $42.6M | $19.8M | $26.6M | $20.1M | $23M | |
| Total Equity | $38.5M | $31.1M | $57.3M | $26M | $151.5M | |
| Total Debt | $7.4M | $5.4M | $5.2M | $4.3M | $5.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.1M | -$34.3M | -$44.8M | -$9.3M | -$16.8M | |
| Cash From Investing | -$152.7K | -$12M | -$121.7M | $9.3M | -$1.7M | |
| Cash From Financing | $66.8M | -$1.2M | $168.3M | -$44.1K | -$40.9K | |
| Free Cash Flow | -$25.3M | -$34.6M | -$45.7M | -$9.3M | -$17.7M | |
SABS
Sector
Market Cap
$274.1M
$23.9M
Price % of 52-Week High
--
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-94.92%
-1.9%
1-Year Price Total Return
210.4%
-18.29%
Beta (5-Year)
0.602
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.84
200-day SMA
Buy
Level
$3.11
Bollinger Bands (100)
Sell
Level
3.62 - 4.16
Chaikin Money Flow
Sell
Level
-4.8M
20-day SMA
Sell
Level
$3.95
Relative Strength Index (RSI14)
Sell
Level
48.56
ADX Line
Buy
Level
17.52
Williams %R
Neutral
Level
-70.3125
50-day SMA
Sell
Level
$4.01
MACD (12, 26)
Buy
Level
1.01
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Sell
Level
-2.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4462)
Sell
CA Score
(Annual)
Level (-1.0687)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-7.6706)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
Stock Forecast FAQ
In the current month, SABS has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SABS average analyst price target in the past 3 months is $9.50.
-
Where Will SAB Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that SAB Biotherapeutics, Inc. share price will rise to $9.50 per share over the next 12 months.
-
What Do Analysts Say About SAB Biotherapeutics, Inc.?
Analysts are divided on their view about SAB Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SAB Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is SAB Biotherapeutics, Inc.'s Price Target?
The price target for SAB Biotherapeutics, Inc. over the next 1-year time period is forecast to be $9.50 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SABS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for SAB Biotherapeutics, Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SABS?
You can purchase shares of SAB Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SAB Biotherapeutics, Inc. shares.
-
What Is The SAB Biotherapeutics, Inc. Share Price Today?
SAB Biotherapeutics, Inc. was last trading at $3.89 per share. This represents the most recent stock quote for SAB Biotherapeutics, Inc.. Yesterday, SAB Biotherapeutics, Inc. closed at $3.88 per share.
-
How To Buy SAB Biotherapeutics, Inc. Stock Online?
In order to purchase SAB Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SABS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SABS
Sector
P/E ratio
--
21.37x
PEG ratio
--
-0.01x
P/B ratio
1.81x
1.72x
Price / LTM sales
884.93x
1.44x
Growth Metrics
SABS
Sector
Revenue growth
-100%
3.44%
Earnings growth
33.75%
14.97%
Revenue (5-year growth)
--
6.27%
Earnings forecast
-$0.17
-$0.22
Profitability
SABS
Sector
Profitability FY 2025
-$3.1M
$2.4M
Return on invested capital
-15.79%
-33.43%
Return on assets
-13.57%
-29.45%
Return on equity
-17.05%
-40.29%
Earnings Date
Last Earnings Date
Mar
27
Next Earnings Date
Apr
5
Estimated Next Earnings Date
Jul
5
Balance Sheet
SABS
Sector
Total cash
$96.6M
$25.6M
Short term investments
$11.9M
$22.7M
Total assets
$174.5M
$70.4M
Long term debt
$5.2M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
